YOUR CHOLESTEROL PANEL IS NOT A CARDIOVASCULAR RISK ASSESSMENT

YOUR CHOLESTEROL PANEL IS NOT A CARDIOVASCULAR RISK ASSESSMENT

Every year, millions of Australians have a cholesterol test through their GP and are told their results look fine. Total cholesterol within range, LDL not too high, HDL reasonable. No action required.

And every year, people with "normal" cholesterol have heart attacks.

This isn't a coincidence or a medical mystery. It's a predictable consequence of using a blunt tool to assess a complex system. A standard lipid panel — the cholesterol test most Australians receive through Medicare — was designed to identify gross abnormalities in lipid levels. It was not designed to give a comprehensive picture of cardiovascular risk. And the difference between those two things can be the difference between catching a problem early and missing it entirely.

WHAT A STANDARD CHOLESTEROL PANEL ACTUALLY MEASURES

A GP-ordered lipid panel through Medicare typically includes four markers:

• Total cholesterol — the sum of all cholesterol in your blood
• HDL — high-density lipoprotein, often called "good" cholesterol
• LDL — low-density lipoprotein, often called "bad" cholesterol
• Triglycerides — circulating fats in the bloodstream

These four numbers have been the foundation of cardiovascular risk assessment for decades. They are useful as a starting point. But they have a fundamental limitation: they tell you the total quantity of cholesterol present, but nothing about the quality, particle size, or inflammatory context that determines whether that cholesterol is actually creating arterial damage.

A high LDL number on a standard panel does not tell you whether your LDL particles are large and buoyant (less atherogenic) or small and dense (highly atherogenic). Those two scenarios carry very different levels of cardiovascular risk — and standard testing cannot distinguish between them.

THE LDL PARTICLE PROBLEM

Not all LDL cholesterol is equal. Research over the past two decades has consistently shown that LDL particle size and density are more predictive of cardiovascular risk than total LDL concentration alone.

Large, buoyant LDL particles (Pattern A) are associated with lower cardiovascular risk. Small, dense LDL particles (Pattern B) are more atherogenic — they penetrate arterial walls more easily, are more susceptible to oxidation, and are more strongly associated with coronary artery disease, metabolic syndrome, and insulin resistance.

A standard LDL result combines all of these subtypes into a single number. You could have a normal total LDL while carrying predominantly small dense particles — the most atherogenic phenotype — and your GP panel would show nothing of concern.

Comprehensive cardiometabolic testing separates LDL into seven subfractions (LDL-1 through LDL-7), identifies your LDL phenotype pattern, and measures mean particle size. This gives you a picture of not just how much LDL you have, but what kind — which is where the clinically meaningful cardiovascular risk information actually lives.

THE MARKERS THAT DON'T APPEAR ON A STANDARD PANEL

Beyond LDL subfractions, a comprehensive cardiometabolic assessment includes several markers that are largely absent from standard GP testing but carry significant predictive value for cardiovascular risk.

Apolipoprotein B (ApoB) is now considered by many cardiologists to be a superior marker of cardiovascular risk compared to LDL cholesterol. Every atherogenic lipoprotein particle — VLDL, IDL, LDL — carries exactly one ApoB molecule. ApoB therefore gives you a direct count of the total number of atherogenic particles in circulation, regardless of their size. Research consistently shows ApoB to be more predictive of cardiovascular events than LDL-C alone, particularly in people with normal or borderline LDL levels.

Lipoprotein(a) — known as Lp(a) — is one of the most underappreciated cardiovascular risk markers in standard clinical practice. It is largely genetically determined, meaning it doesn't respond significantly to diet or lifestyle changes, and elevated levels are independently associated with increased risk of heart attack, stroke, and aortic valve disease. It is not included in a standard Medicare lipid panel. Many people with elevated Lp(a) have no idea — because they've never been tested.

High-sensitivity CRP (hsCRP) measures low-grade systemic inflammation — a key driver of atherosclerosis and cardiovascular events that is completely invisible to a standard cholesterol test. Research has established that inflammation is not just a consequence of cardiovascular disease but an active contributor to its development. A person can have entirely normal cholesterol but elevated hsCRP, placing them at significantly elevated cardiovascular risk — a risk that would go completely undetected on a standard lipid panel.

Homocysteine is an amino acid that, when elevated, directly damages arterial walls and promotes clot formation. Elevated homocysteine is an independent risk factor for cardiovascular disease, stroke, and peripheral arterial disease — and it is also a functional marker of B vitamin status and methylation pathway efficiency. It is rarely tested through a standard GP consultation despite being both clinically significant and highly modifiable with targeted B vitamin support.

VLDL and IDL subfractions add further granularity to the lipid picture — elevated IDL-3 in particular is associated with raised Lipoprotein(a) levels and increased atherogenic risk, a connection that a standard panel cannot make.

THE GLUCOSE CONNECTION

A comprehensive cardiometabolic assessment also includes fasting glucose — not as a standalone diabetes screen, but as part of the metabolic risk picture. Fasting glucose sitting at the high end of the normal range, combined with elevated triglycerides and low HDL, paints a picture of early metabolic dysfunction and insulin resistance that significantly elevates cardiovascular risk long before a diabetes diagnosis would be made.

Early metabolic dysfunction is one of the most modifiable cardiovascular risk factors — but only if it's identified early enough to act on.

WHAT THIS LOOKS LIKE IN PRACTICE

Consider two people who both receive a standard GP cholesterol panel showing total cholesterol of 5.8 mmol/L, LDL of 3.6 mmol/L, HDL of 1.2 mmol/L, and triglycerides of 1.4 mmol/L. On a standard panel, both results look similar and would likely receive the same clinical response.

Now add comprehensive cardiometabolic testing. Person A has large buoyant LDL particles (Pattern A), low ApoB, normal Lp(a), low hsCRP, and a normal homocysteine. Their risk profile, despite the borderline LDL, is actually reassuring.

Person B has a predominantly small dense LDL phenotype, elevated ApoB, elevated Lp(a), elevated hsCRP indicating active inflammation, and homocysteine at 16 µmol/L — well above the optimal range. Their cardiovascular risk picture is significantly more concerning — and completely invisible on the standard panel both people received.

Same cholesterol number. Entirely different risk profile. Only one of them knows.

WHO SHOULD BE LOOKING BEYOND THE STANDARD PANEL

Comprehensive cardiometabolic testing is relevant for anyone who wants a genuine picture of their cardiovascular risk — not just a pass or fail on four markers. It is particularly relevant for people with a family history of cardiovascular disease, those with borderline or elevated cholesterol on standard testing, anyone experiencing early metabolic symptoms, people with elevated inflammation or known autoimmune conditions, and anyone interested in a proactive longevity-focused approach to their health.

It is also worth noting that cardiovascular disease remains the leading cause of death in Australia. For a condition that is significantly influenced by modifiable risk factors — lipid particle size, inflammation, homocysteine, metabolic health — having access to a comprehensive risk assessment is not a luxury. It is one of the most important investments in long-term health available.

THE TAKEAWAY

A standard cholesterol panel tells you whether your total lipid numbers fall within a population reference range. A comprehensive cardiometabolic assessment tells you how your cardiovascular system is actually functioning — the quality of your lipid particles, the inflammatory burden on your arteries, the hidden genetic risk factors, and the early metabolic signals that standard testing cannot see.

Four numbers is not a cardiovascular risk assessment. It's the beginning of one.

WANT A COMPLETE PICTURE OF YOUR CARDIOVASCULAR HEALTH?

The Optimum Testing Cardiometabolic Test goes well beyond a standard cholesterol panel — assessing LDL subfractions and phenotype, ApoB, Lipoprotein(a), hsCRP, homocysteine, fasting glucose, and more. Results are interpreted by a clinical nutritionist against optimal reference ranges, with a personalised protocol built around your individual risk profile and health goal.

Explore the Cardiometabolic Test →